Targeting population entering phase III trials: A new stratified adaptive phase II design

Statistics in Medicine

Volumn 30, Issue 8, 2011, Pages 801-811

  Tournoux Facon, Caroline ^a,b,c,d   Rycke, Yann De ^e   Tubert Bitter, Pascale ^c,d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT CURIE   (France)

Author keywords

Adaptive phase II design; Stratification; Target population

Indexed keywords

ARTICLE; CONTROLLED STUDY; INTERMETHOD COMPARISON; PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; PROCESS DEVELOPMENT; RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE; STRATIFIED SAMPLE; STUDY DESIGN;

ANTINEOPLASTIC PROTOCOLS; BIOSTATISTICS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MODELS, STATISTICAL; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 79953002523     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4148     Document Type: Article

References (12)

1. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997; 16:2701-2711.
2. London WB, Chang MN. One- and two-stage designs for stratified phase II clinical trials. Statistics in Medicine 2005; 24:2597-2611.
3. Jones CL, Holmgren E. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies. Contemporary Clinical Trials 2007; 28:654-661.
4. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
5. Pierga JY, Mathiot C, Extra JM, Tresca P, Asselah J, Sigal-Zafrani B, Brain E, Diéras V, Mignot L, Marty M. Circulating tumor celles detection in a randomized phase II trial of neoadjuvant chemotherapy for large operable and locally advanced breast cancer (REMAGUS 02): preliminary results. Journal of Clinical Oncology 2006; 24:10637. ASCO Annual Meeting Proceedings Part I.
6. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004; 57:229-236.
7. Grouin JM, Coste M, Lewis J. Subgroup analyses in randomized clinical trials: statistical and regulatory issues. Journal of Biopharmaceutical Statistics 2005; 15:869-882.
8. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine 2002; 21:2917-2930.
9. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? European Journal of Cancer 2008; 44:8-11.
10. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. European Journal of Cancer 2009; 45:275-280.
11. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 2005; 23:2020-2027.
12. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine 2003; 22:763-780.